Edward Dyson

Associate

+44 (0) 20 7556 4230
edyson@cooley.com

Edward Dyson practices corporate and securities law, with an emphasis on the representation of late-stage private and public companies, their major shareholders and investment banks in primary and secondary securities offerings, public and private mergers, acquisitions and disposals, and regularly provides advice in relation to on-going reporting obligations and governance matters in the UK and US.

Download full bio

Experience

  • Jazz Pharmaceuticals Acquisition of Redx Pharma's pan-RAF Inhibitor Program Valued up to $206 Million 

  • RenalytixAI – £22 Million IPO 

  • Endava – $146 Million IPO 

  • Endava – $146 Million IPO 

  • Autolus – $173 Million IPO 

  • View all

Education

  • College of Law, Moorgate
    LPC, 2009

  • University of Durham
    LL.B (Hons), 2008

Media & Insight

Contact

+44 (0) 20 7556 4230 office
edyson@cooley.com

Dashwood
69 Old Broad Street
London, UK EC2M 1QS